On November 10, IDEXX Laboratories recorded an Intraday Rise of 3.04% in Regular Trading, trading around $697.25, with turnover of $168 million.
The move was supported by the company’s previously reported third-quarter results that exceeded market expectations and by a higher full-year outlook.
IDEXX Laboratories reported third-quarter comparable EPS of $3.96 on revenue of $1.21 billion, above consensus expectations of $3.73 and $1.19 billion, respectively. The company also raised its full-year comparable EPS growth outlook to 15% to 16% from 13% to 15%, and lifted revenue guidance to $4.74 billion to $4.77 billion from $4.70 billion to $4.75 billion. Additional follow-through came from analysts highlighting resilient pricing despite softer veterinary visit trends, while a major broker also raised its price target to $800 from $740 shortly after the results.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments